Literature DB >> 23239521

Hepatitis C screening: getting it right.

Brian R Edlin1.   

Abstract

UNLABELLED: Hepatitis C is the most prevalent bloodborne viral disease in the United States and the deadliest. This year, the U.S. Preventive Services Task Force (USPSTF) will update its 2004 hepatitis C guideline, which recommends against screening asymptomatic adults for hepatitis C. This guideline has hampered public health efforts to encourage screening and identify and refer infected persons for care by declaring that such interventions were not supported by the evidence. A draft revision of the guideline, released on November 26, 2012, concludes that testing persons born between 1945 and 1965 probably has at least a small net benefit, but stops short of definitively recommending that this cohort be screened. This article examines the Task Force's process for writing its guidelines. It recommends that the Task Force adopt a balanced approach to evaluating the benefits and harms of screening; use the preponderance of the evidence as a standard for evaluating interventions that target serious public health problems; be transparent about the value judgments that go into its decisions; consider the wide variation in disease prevalence in diverse patient populations; and recommend screening asymptomatic adults for hepatitis C.
CONCLUSION: By taking a broader view of the evidence, the Task Force can write new guidelines that will serve efforts to curb the hepatitis C epidemic, rather than frustrate them.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 23239521      PMCID: PMC4751877          DOI: 10.1002/hep.26194

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Current methods of the US Preventive Services Task Force: a review of the process.

Authors:  R P Harris; M Helfand; S H Woolf; K N Lohr; C D Mulrow; S M Teutsch; D Atkins
Journal:  Am J Prev Med       Date:  2001-04       Impact factor: 5.043

2.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

3.  Screening for hepatitis C virus infection in adults: recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

4.  The meaning of the U.S. Preventive Services Task Force grade I recommendation: screening for hepatitis C virus infection.

Authors:  Ned Calonge; Gurvaneet Randhawa
Journal:  Ann Intern Med       Date:  2004-11-02       Impact factor: 25.391

Review 5.  Manifestations of chronic hepatitis C virus infection beyond the liver.

Authors:  Ira M Jacobson; Patrice Cacoub; Luigino Dal Maso; Stephen A Harrison; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-24       Impact factor: 11.382

6.  Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma.

Authors:  Christopher J Sonnenday; Justin B Dimick; Richard D Schulick; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2007-10-03       Impact factor: 3.452

7.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

8.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States.

Authors:  David B Rein; John S Wittenborn; Cindy M Weinbaum; Miriam Sabin; Bryce D Smith; Sarah B Lesesne
Journal:  Dig Liver Dis       Date:  2010-06-17       Impact factor: 4.088

9.  Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Authors:  Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

10.  Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials.

Authors:  Nina Kimer; Emilie Kristine Dahl; Lise Lotte Gluud; Aleksander Krag
Journal:  BMJ Open       Date:  2012-10-22       Impact factor: 2.692

View more
  8 in total

1.  Increasing hepatitis C screening in a large integrated health system: science and policy in concert.

Authors:  Carla V Rodriguez; Kevin B Rubenstein; Benjamin Linas; Haihong Hu; Michael Horberg
Journal:  Am J Manag Care       Date:  2018-05-01       Impact factor: 2.229

2.  Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population.

Authors:  Roland C Merchant; Janette R Baird; Tao Liu; Lynn E Taylor; Brian T Montague; Ted D Nirenberg
Journal:  Acad Emerg Med       Date:  2014-07       Impact factor: 3.451

3.  HCV among The Miriam Hospital and Rhode Island Hospital Adult ED Patients.

Authors:  Roland C Merchant; Janette R Baird; Tao Liu; Lynn E Taylor
Journal:  R I Med J (2013)       Date:  2014-07-01

4.  Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Authors:  V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault
Journal:  Aliment Pharmacol Ther       Date:  2014-03-24       Impact factor: 8.171

5.  Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up.

Authors:  Amit G Singal; Tushar D Dharia; Peter F Malet; Saleh Alqahtani; Song Zhang; Jennifer A Cuthbert
Journal:  BMJ Open       Date:  2013-09-03       Impact factor: 2.692

6.  Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus.

Authors:  Dennis G Fisher; Kristen L Hess; Erlyana Erlyana; Grace L Reynolds; Catherine A Cummins; Todd A Alonzo
Journal:  Open Forum Infect Dis       Date:  2015-07-07       Impact factor: 3.835

7.  Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.

Authors:  James G Carlucci; Syeda A Farooq; Lindsey Sizemore; Michael Rickles; Brandon Cosley; Leigh McCormack; Carolyn Wester
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

8.  Continuum of hepatitis C care in France: A 20-year cohort study.

Authors:  Coralie Hermetet; Frederic Dubois; Catherine Gaudy-Graffin; Yannick Bacq; Bernard Royer; Christophe Gaborit; Louis D'Alteroche; Jean Claude Desenclos; Philippe Roingeard; Leslie Grammatico-Guillon
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.